Who LUTATHERA Could Help
LUTATHERA has been shown to help people with NETs in 2 separate clinical trials.
Trial 1: LUTATHERA Was Studied in People Who Had Already Tried Long-Acting Octreotide Alone
This clinical trial studied 229 people with NETs in their midgut. They either received LUTATHERA in combination with 30 mg of long-acting octreotide or 60 mg of long-acting octreotide alone.
Longer Time Without Disease Progression for Patients Treated With LUTATHERA | |
People taking LUTATHERA were 79% less likely to have their cancer worsen or die compared with people taking 60 mg of long-acting octreotide alone. |  |
| More people treated with LUTATHERA had their tumors shrink or disappear compared with people treated with 60 mg of long-acting octreotide alone | |
13% of peoplein the LUTATHERA with 30 mg of long-acting octreotide group
Partial response (tumors shrink)a:
| 4% of peoplein the 60 mg of long-acting octreotide group
Partial response (tumors shrink)a:
0% (0 of 113 people) |
a Tumors shrink by ≥30% from baseline.
b Tumors disappear and cancerous lymph nodes shrink to <10 mm. The disappearance of any measurable tumors does not necessarily mean that the cancer is completely gone.
Trial 2: LUTATHERA Was Studied in People Who Were Newly Diagnosed With GEP-NETs
This clinical trial studied 226 people with NETs in their GI tract, particularly in the pancreas or small intestine. They either received LUTATHERA in combination with 30 mg of long-acting octreotide or 60 mg of long-acting octreotide alone.
Longer Time Without Disease Progression for Patients Treated With LUTATHERA | |
People taking LUTATHERA were 72% less likely to have their cancer worsen or die compared with people taking 60 mg of long-acting octreotide alone. |  |
| More people treated with LUTATHERA had their tumors shrink or disappear compared with people treated with 60 mg of long-acting octreotide alone | |
43% of peoplein the LUTATHERA with 30 mg of long-acting octreotide group
Partial response (tumors shrink)c:
| 9% of peoplein the 60 mg of long-acting octreotide group
Partial response (tumors shrink)c:
0% (0 of 75 people) |
c Tumors shrink by ≥30% from baseline.
d Tumors disappear and cancerous lymph nodes shrink to <10 mm. The disappearance of any measurable tumors does not necessarily mean that the cancer is completely gone.
